Registration Strip Icon for pro Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.

ADCT

ADC Therapeutics (ADCT)

ADC Therapeutics SA
Date:
Sort by:
 Showing the most relevant articles for your search:NYSE:ADCT
DateTimeSourceHeadlineSymbolCompany
03/01/202508:05PR Newswire (US)ADC Therapeutics Makes Grants to New Employees Under Inducement PlanNYSE:ADCTADC Therapeutics SA
31/12/202408:30PR Newswire (US)ADC Therapeutics Announces Completion of Enrollment of Phase 3 Confirmatory Clinical Trial of ZYNLONTA® in Combination with Rituximab in 2L+ Diffuse Large B-Cell LymphomaNYSE:ADCTADC Therapeutics SA
11/12/202423:30PR Newswire (US)ADC Therapeutics Announces Positive Initial Data from LOTIS-7 Clinical Trial Evaluating ZYNLONTA® in Combination with Bispecific Antibody in Patients with Relapsed/Refractory Diffuse Large B-cell LymphomaNYSE:ADCTADC Therapeutics SA
10/12/202412:42Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNYSE:ADCTADC Therapeutics SA
10/12/202412:39Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNYSE:ADCTADC Therapeutics SA
10/12/202412:30Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNYSE:ADCTADC Therapeutics SA
09/12/202423:30PR Newswire (US)ADC Therapeutics Announces The Lancet Haematology Publication of Data from Investigator-Initiated Trial Evaluating ZYNLONTA® in Combination with Rituximab to Treat Relapsed/Refractory Follicular LymphomaNYSE:ADCTADC Therapeutics SA
06/12/202423:30PR Newswire (US)ADC Therapeutics to Provide Initial Data Update on LOTIS-7 Clinical TrialNYSE:ADCTADC Therapeutics SA
03/12/202408:30PR Newswire (US)ADC Therapeutics Makes Grants to New Employees Under Inducement PlanNYSE:ADCTADC Therapeutics SA
08/11/202402:44Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NYSE:ADCTADC Therapeutics SA
07/11/202423:54Edgar (US Regulatory)Form 8-K - Current reportNYSE:ADCTADC Therapeutics SA
07/11/202423:30PR Newswire (US)ADC Therapeutics Reports Third Quarter and Year-to-Date 2024 Financial Results and Provides Operational UpdateNYSE:ADCTADC Therapeutics SA
06/11/202401:47PR Newswire (US)ADC Therapeutics Announces Investigator-Initiated Study Abstracts Accepted for Presentation at the 66th ASH Annual MeetingNYSE:ADCTADC Therapeutics SA
04/11/202423:15PR Newswire (US)ADC Therapeutics to Present at November Investor ConferencesNYSE:ADCTADC Therapeutics SA
02/11/202407:05PR Newswire (US)ADC Therapeutics Makes Grants to New Employees Under Inducement PlanNYSE:ADCTADC Therapeutics SA
31/10/202422:15PR Newswire (US)ADC Therapeutics to Host Third Quarter 2024 Financial Results Conference Call on November 7, 2024NYSE:ADCTADC Therapeutics SA
02/10/202406:05GlobeNewswire Inc.ADC Therapeutics Makes Grants to New Employees Under Inducement PlanNYSE:ADCTADC Therapeutics SA
24/09/202406:39Edgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNYSE:ADCTADC Therapeutics SA
24/09/202406:35Edgar (US Regulatory)Form DEF 14A - Other definitive proxy statementsNYSE:ADCTADC Therapeutics SA
14/09/202406:16Edgar (US Regulatory)Form PRE 14A - Other preliminary proxy statementsNYSE:ADCTADC Therapeutics SA
04/09/202406:05GlobeNewswire Inc.ADC Therapeutics Makes Grants to New Employees Under Inducement PlanNYSE:ADCTADC Therapeutics SA
03/09/202421:15GlobeNewswire Inc.ADC Therapeutics to Present at Upcoming Investor ConferencesNYSE:ADCTADC Therapeutics SA
14/08/202414:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNYSE:ADCTADC Therapeutics SA
07/08/202406:26Edgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933NYSE:ADCTADC Therapeutics SA
07/08/202400:06Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NYSE:ADCTADC Therapeutics SA
06/08/202421:37Edgar (US Regulatory)Form 8-K - Current reportNYSE:ADCTADC Therapeutics SA
06/08/202421:30GlobeNewswire Inc.ADC Therapeutics Reports Second Quarter 2024 Financial Results and Provides Operational UpdateNYSE:ADCTADC Therapeutics SA
02/08/202406:05GlobeNewswire Inc.ADC Therapeutics Makes Grants to New Employees Under Inducement PlanNYSE:ADCTADC Therapeutics SA
30/07/202421:15GlobeNewswire Inc.ADC Therapeutics to Host Second Quarter 2024 Financial Results Conference Call on August 6, 2024NYSE:ADCTADC Therapeutics SA
08/07/202416:00GlobeNewswire Inc.Myricx Bio Announces £90m ($114m) Series A Financing to Advance its Novel NMTi-ADC Therapeutics into Clinical DevelopmentNYSE:ADCTADC Therapeutics SA
 Showing the most relevant articles for your search:NYSE:ADCT

Your Recent History

Delayed Upgrade Clock